Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm salivating for oil, looking at the monster volume... lot of pent up energy... even bigger than the last run to 140+ it's been horizontal at 100.
http://finviz.com/futures_charts.ashx?t=CL&p=w1
thumbs up
I'm out now... I was going against my bearishness about the data when I bought. This has zero vig going into the PDUFA so if it is a suprise, congrats to those that held.
nice. I have posted here and there about the gappyness of the compq... the two gaps on either side of the 200sma. right now, almost every stock has a gap, here or there. A pullback to 200sma (daily) would be sweet
I think the trendlines you drew are very similar to the trendlines during QE periods... I wasn't very careful in drawing lines on this but it illustrates the point:
They've been ATMing on the Australian market and the price has still been going up. Biotechs are winding off overbought conditions.
It would be nice to see them get it over with in one lump though.
http://www.reuters.com/finance/stocks/PBT.AX/key-developments
I may be paranoid but when things go that way I think they are fishing for your ID.
What is also amazing is the long history of complications in trying to target this pathway, FKBP. Check out "billion dollar molecule" if you haven't already.
http://www.amazon.com/Billion-Dollar-Molecule-Companys-Perfect/dp/0671510576
one theme I've seen on charts is "gap and run" on so many stocks gapped up sometime in january... and even the $compq (one gap below 200sma and one just above it)
these gaps are fuel for shorts and they could dig a whole for themselves if they get too short.
not rida... Bellicum...AP1903
http://www.bellicum.com/pipeline/ap1903
BACKGROUND OF THE INVENTION
Identification of the immunophilin protein, FKBP12, as a specific receptor for the powerful immunosuppressant drug, FK506, led to a burst of pharmaceutical research over the past decade. Much of that research was aimed at the discovery of other high affinity ligands for FKBP which might become clinically and commercially significant immunosuppressant agents. A variety of synthetic FKBP ligands were produced and evaluated, but with disappointing results. In the early 1990's it was learned that FK506 works, not simply by binding to FKBP, but by mediating the association of FKBP with the effector protein, calcineurin, to form the tripartite complex which actually mediates immunosuppression. This finding explained the absence of immunosuppressive activity for the many high-affinity FKBP ligands which are now known in the art. A body of synthetic knowledge pertaining to the design and synthesis of FKBP ligands had been developed which appeared destined to lie fallow. See e.g., U.S. Pat. Nos. 5,192,773; 5,330,993; WO 92/19593; and WO 94/07858.
Largely independent of the search for new immunosuppressive agents, however, pioneering work on the design, production and use of biological switches based on ligand-mediated multimerization of recombinant proteins, including immunophilin-based fusion proteins, was reported. See Spencer et al, 1993, Science 262:1019-1024 and International Patent Applications PCT/US94/01660 and PCT/US94/08008. Spencer et al reported a new class of biologically active substances based on dimers of FK506, covalently attached to each other via a synthetic linker moiety. The resultant dimers ("FK1012" molecules) are characterized by high binding affinities for immunophilin molecules and are capable of mediating the association or complexation of fusion proteins containing FKBP domains. However, FK1012 and related semisynthetic multimerizing agents are large, complex molecules which can be inconvenient to produce.
New methods and materials for multimerizing chimeric proteins containing immunophilin moieties would be desirable, where the methods and materials involve smaller, simpler multimerizing agents which are more convenient to produce and which are more readily amenable to structural modification.
Important initial research based on N-oxalyl-pipecolyl and N-oxalyl-prolyl ligand moieties and aimed at providing wholly synthetic replacements for FK1012-type semi-synthetic multimerizing agents was disclosed in PCT/US95/10559. Further progress in this direction, including new multimerizing agents e.g. which are more conveniently prepared, have alternative pharmacokinetic profiles and/or which bind preferentially or with higher affinity to genetically engineered immunophilin domains relative to their binding to native immunophilin proteins would be very desirable.
nice strong market... i'm happy to see pran above 200sma on volume.
things are running up on anticipation of this or that and the market seems super strong now... new highs on naz... white hot IPO market... white hot biotech M&A
fda is humming on all cylinders right now.
news is being sold... look at CRIS... had a little fda runnup but early suprise... sell off... didn't even have time to run.
CORT has me scratching my head.
Ihub board for facebook:
http://investorshub.advfn.com/boards/board.aspx?board_id=22857
true...CRIS yesterday big suprise as evidence.
CORT is coming up.
Thanks Hp, np and dew for this discussion.
facebook on cnbc now says 3/4 of facebook users are outside us.
stock symbol FB
I think this matters for the Global Demographic Tailwind.... S-1 in link below and bloomberg article under that.
http://www.sec.gov/Archives/edgar/data/1326801/000119312512034517/d287954ds1.htm
http://www.bloomberg.com/news/2012-02-01/facebook-files-to-raise-up-to-5-billion-in-ipo-of-social-networking-site.html
Facebook Registers for $5B IPO
QBy Brian Womack and Ari Levy - Feb 1, 2012 5:25 PM ET .
QFeb. 1 (Bloomberg) -- Facebook Inc., the social-networking website that began about eight years ago in a Harvard University dorm, filed to raise $5 billion in an initial public offering. Bloomberg's Cory Johnson speaks with Trish Regan, Lisa Murphy and Adam Johnson on Bloomberg Television's "Street Smart." (Source: Bloomberg)
.Facebook Inc., the social-networking website that began about eight years ago in a Harvard University dorm, filed to raise $5 billion in an initial public offering in what would be the largest Internet IPO on record.
Facebook, which now boasts more than 800 million users, didn’t specify the number or price of shares it will offer in a regulatory filing today. The $5 billion amount is a placeholder used to calculate fees and may change. The Menlo Park, California-based company hired Morgan Stanley, JPMorgan Chase & Co., Goldman Sachs Group Inc., Bank of America Corp., Barclays Plc and Allen & Co. to manage the IPO.
Co-founded in 2004 by then 19-year-old Mark Zuckerberg, Facebook has grown into the dominant social-networking company, squelching competitors such as MySpace Inc. Revenue in 2011 surged 88 percent to $3.71 billion, with about 85 percent coming from advertising, according to the filing.
“Investors are still very much willing to pay up for growth,” Paul Bard, director of research at the investment- advisory firm Renaissance Capital LLC in Greenwich, Connecticut, said before the filing. “There’s just phenomenal interest in this company and its potential.”
Facebook is considering a valuation of $75 billion to $100 billion, two people with knowledge of the matter said last week. At the high end of the range, that would value Facebook at 26.9 times trailing 12-month sales, more than double Google Inc. (GOOG)’s valuation when the search-engine operator went public in 2004.
Earnings Surge
The stock would trade under the symbol FB on either the Nasdaq Stock Market or the New York Stock Exchange. The company plans to use the proceeds for working capital and other general corporate purposes.
Net income last year surged by almost two-thirds to $1 billion, the filing showed. Last year, Facebook said it expects U.S. regulators to require that it disclose financial results by April 30, 2012, if the company hasn’t gone public by then. Facebook decided to wait until 2012 for its IPO to give Zuckerberg more time to gain users and boost sales, people familiar with the matter said in 2010.
Zuckerberg is the company’s top shareholder, the filing shows. Accel Partners remains the top outside stakeholder with 11.4 percent of the investor votes, while Dustin Moskovitz, one of Zuckerberg’s co-founders, holds 7.6 percent voting power.
Facebook would follow a crop of social-media companies that went public in 2011, the biggest year for U.S. Internet IPOs in more than a decade, according to Bloomberg data. Nineteen companies raised $6.6 billion in 2011, the most since 101 raised $11 billion in 2000, the data show.
Internet IPOs
Professional-networking site LinkedIn Corp., music- streaming service Pandora Media Inc., daily-deal site Groupon Inc. and social-gaming company Zynga Inc. all sold shares last year.
Led by Chief Executive Officer Zuckerberg, 27, Facebook is increasing its focus on mobile technology to take advantage of the shift to smartphones and tablets. It expects its next 1 billion users to come mainly from mobile devices, rather than desktop computers.
The company made at least 10 acquisitions in 2011, including group-messaging service Beluga in March. In addition to buying startups, Facebook has enabled hundreds of others to get off the ground by offering an easy, cheap and fast way for them to reach millions of potential customers, said Shervin Pishevar, a managing director at Menlo Ventures in Menlo Park, California.
“There will be a lot of $1 billion-plus companies built on these platforms,” said Pishevar, who owns Facebook shares.
Accel’s Stake
Venture firm Accel Partners first led a $12.7 million investment in Facebook in 2005. Other investors include Microsoft Corp. and PayPal co-founder Peter Thiel, as well as Greylock Partners.
As the site’s popularity grew, banks, hedge funds and mutual fund companies started buying stock. In January 2011, Facebook said it raised $1.5 billion in a financing round led by Goldman Sachs Group Inc. that valued the company at $50 billion. Goldman Sachs, funds managed by the firm, and Digital Sky Technologies bought $500 million of stock, while Goldman Sachs offered $1 billion of shares to non-U.S. clients.
While Facebook has steadily added users since its creation, it has faced increased scrutiny over its protection of user data. In November, the company agreed to settle privacy complaints with the Federal Trade Commission. The move may help allay criticism that it doesn’t do enough to shield the information it prods users into sharing.
BIOTECH mayhem!!!!
I bought 1000 shares today... I had no shares recently.... was feeling gloomy. chart looks neat and fda is promising to be quicker about approving things... even though corcept didn't get accelerated approval.
I think 88% of the people in the trial are still taking corlux, I think.
where'd you get that idea?
what do you mean?
SHEEEsh I just checked cris.... big high volume prints this morning.
It is posible that the first patients could be dosed some day this week, according to the protocol synopsis:
FDA Approval to Commence Huntington's Disease Clinical Trial Using Prana's PBT2
Huntington Study Group Appointed to Coordinate the Trial and Start Recruitment
Press Release: Prana Biotechnology – Wed, Jan 4, 2012 10:53 AM EST
MELBOURNE, AUSTRALIA--(Marketwire -01/04/12)- Prana Biotechnology (NASDAQ: PRAN - News) (ASX: PBT.AX - News) today announced that it has received approval from the United States Food and Drug Administration (FDA) to start recruiting patients for the company's first clinical trial using PBT2 in patients with Huntington's Disease (HD).
Prana's Investigational New Drug Application (IND) is now open. "The opening of this IND for a Phase 2 study follows an extensive review of PBT2 data by the FDA and reflects a favourable analysis from the FDA to support the study of PBT2 in Huntington's Disease patients", commented Geoffrey Kempler, Prana's Executive Chairman.
Huntington's Disease is a complex and severely debilitating genetic, neurodegenerative disease, for which there is no cure. The disease often affects young adults and, whilst associated with severe physical movement symptoms, progressively impacts the mind and emotions as well. The disease causes incapacitation and death about 15-25 years after onset.
The Company has appointed the Huntington Study Group (HSG) to coordinate the trial. HSG will commence recruitment of patients for the trial, named "Reach2HD, at clinical sites across USA and in Australia. The randomised, double-blind, placebo-controlled trial will enrol 100 patients with early to mid-stage Huntington's Disease. The Principal Investigator on the study is Dr. Raymond Dorsey of Johns Hopkins University Medical Center. The protocol synopsis appears below in Appendix 1.
Professor Ira Shoulson, Professor of Neurology, Pharmacology and Human Science at Georgetown University (Washington DC) and the Chair of the Executive Committee of the Huntington Study Group said "PBT2 attracted our attention as an experimental drug with the potential to bring real benefit to Huntington's Disease patients who suffer from a range of motor, behavioural and cognitive symptoms. The favourable signals from the PBT2 trial in Alzheimer's Disease are particularly promising".
The disease affects 30,000 people in the US and about 70,000 worldwide. There are no drugs in development that have established clinical evidence for treating cognitive decline. Prana aims, in this trial, to demonstrate safety, motor benefits and the same cognitive benefits for Huntington's patients that it has already demonstrated in Alzheimer's patients treated with PBT2.
Appendix 1 - Protocol synopsis
Title
A randomised, double-blind, placebo-controlled study to assess the safety and tolerability, and efficacy of PBT2 in patients with early to mid-stage Huntington's disease (HD)
Study Number
PBT2-204
Study Name/Acronym
Reach2HD
Study Design
Randomised, double-blind, placebo-controlled, parallel group, multi-centre, Phase 2a study.
Objectives
Primary objective:
To evaluate the safety and tolerability of two dose levels of PBT2 when administered orally once daily over 26 weeks in patients with HD.
Secondary objectives:
Determine the effect of PBT2 after 26 weeks in patients with HD on:
1. Cognition
2. Motor function
3. Behaviour
4. Functional abilities
5. Global function
6. Plasma and urine biomarkers
7. Brain volumes and function (imaging), and
8. To evaluate the Pharmacokinetics of PBT2 in patients with HD.
Number of Patients
It is planned that 100 patients will be randomised in to the study.
Key Patient Criteria
•Men and women with Total Functional Capacity (TFC) 6-13, inclusive, and a CAG repeat number of = 36
•Montreal Cognitive Assessment (MoCA) score = 12
Doses
Placebo (0mg PBT2), 100mg PBT2 and 250mg PBT2, once daily capsules.
Per Patient Duration
34 weeks: Four week Screening period, 6 months (26 weeks) treatment period and Follow-up 4 weeks post treatment.
Endpoints
Primary
•Safety and Tolerability assessments.
Secondary
•Cognition Tests: Cognitive Test Battery (consisting of Category Fluency Test, Trail Making Test parts A and B, Map Search, Symbol Digit Modalities Test and Unified Huntington Disease Rating Scale (UHDRS) Stroop Word Reading). MoCA.
•Motor Function Tests: UHDRS '99 Motor component; Speeded Tapping Task.
•Behaviour: UHDRS Behavioural component.
•Functional Abilities: Total Functional Capacity and Independence Scale from UHDRS '99; Schwab & England Activities of Daily Living Scale (SEADL).
•Subject and investigator global assessments: Patient Reported Outcomes; Clinical Global Impression - Severity Scale.
•Biomarkers: small molecule markers of metabolic and oxidative stress in blood and urine; blood levels of total and mutant huntingtin; gene expression markers of HD progression; plasma selenium.
•Brain Imaging: volumetric and functional measures.
•Pharmacokinetics: sparse sampling.
Trial Locations
•Australia
•USA
Trial Standard
Study will be conducted according to ICH GCP
About Prana Biotechnology Limited
Prana Biotechnology was established to commercialize research into age-related neurodegenerative disorders. The Company was incorporated in 1997 and listed on the Australian Securities Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.
For further information please visit the Company's web site at www.pranabio.com.
The Huntington Study Group
(www.huntington-study-group.org).
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, PBT2, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to, PBT2, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, PBT2, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, the intellectual property relating to PBT2, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on management's current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.
..Contact:.
.
Australia
Whales are mammals, fish have fins, whales have flippers.
GL to you too. If it closes the gap I'll remind you.
compare bioline to pran...
$35M market cap $50M
many shots on many goals. two shots on two goals.
Hey dude good luck. I'm out at $12.
50sma was easy to get to. Whales wait for there price when they have time.
When will they tell us more specifically what protein they are targeting with their molecule?
Good position to start. I was in this before the news and was shocked and pleased. The company has many shots on many goals... like a holding company... which many people think could be a sign of a "scam".
They will get good cash from this PR... I am not the only one who thinks it. They like to keep at least $30M. They have plenty on the shelf to sell. Just whether it will be $5... or $4... I think the stock will close this gap if they don't partner something to generate cash.
$5 is ironic, because that was the pps low on the first day on Nasdaq.
If they could pull off a partnership for any of their assets right now it will never close that gap, and they could sell shares at a nice high price.
Its gonna be weird when the volume dries up.